{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:25:21Z","timestamp":1769603121215,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.transci.2022.103367","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T08:40:56Z","timestamp":1643013656000},"page":"103367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6961-8971","authenticated-orcid":false,"given":"Seval","family":"Akpinar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omur","family":"Kayikci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Tekgunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2022.103367_bib0005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12185-015-1785-1","article-title":"State-of-the-art acute and chronic GVHD treatment","volume":"101","author":"Jamil","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.transci.2022.103367_bib0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","article-title":"Posttransplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EMBT","volume":"14","author":"Sanz","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.transci.2022.103367_bib0015","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers a systematic review and meta-analysis","volume":"5","author":"Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.transci.2022.103367_bib0020","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/bloodadvances.2020001499","article-title":"Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation","volume":"4","author":"Al Malki","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2022.103367_bib0025","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplant cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103367_bib0030","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2022.103367_bib0035","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bbmt.2015.01.020","article-title":"Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease","volume":"21","author":"Bradstock","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0040","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1080\/10428194.2016.1266624","article-title":"Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"58","author":"Arai","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"428","key":"10.1016\/j.transci.2022.103367_bib0045","first-page":"e1","article-title":"Experience using anti-thymocyte globulin with post-transplantation cyclophophamide for graft-versus-host disease prophylaxis in peripheral blood haploidentical stem cell transplantation","volume":"27","author":"Salas","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.transci.2022.103367_bib0050","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41409-021-01358-y","article-title":"Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation","volume":"56","author":"Xi","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0055","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haematopoietic stem-cell transplantation: an open-label, phase 3, randomized controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2022.103367_bib0060","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","article-title":"Prophylactic, preemptive, and curative treatment of sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.transci.2016.01.009","article-title":"Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation?","volume":"54","author":"Tekgunduz","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2022.103367_bib0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0075","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0080","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0085","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.transci.2022.103367_bib0090","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2022.103367_bib0095","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"EBMT risk score","volume":"47","author":"Grathwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0100","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103367_bib0105","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GvHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"Sep 21","key":"10.1016\/j.transci.2022.103367_bib0115","article-title":"Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia","author":"Wieduwilt","year":"2021","journal-title":"Blood Adv"},{"issue":"June 25","key":"10.1016\/j.transci.2022.103367_bib0120","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2022.103367_bib0125","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2022.103367_bib0130","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2022.103367_bib0135","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.13977","article-title":"Post-transplant cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation","volume":"173","author":"Mehta","year":"2016","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.transci.2022.103367_bib0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ejh.12541","article-title":"OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation","volume":"96","author":"Holtick","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2022.103367_bib0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.transci.2022.103367_bib0150","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for heamatological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.transci.2022.103367_bib0155","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors","volume":"13","author":"Brissot","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.transci.2022.103367_bib0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"Battipaglia","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.transci.2022.103367_bib0170","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jtct.2021.06.018","article-title":"Post-transplant cyclophosphamide versus thymoglobulin in HLA-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome","volume":"27","author":"Modi","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.transci.2022.103367_bib0175","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.16621","article-title":"Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation","volume":"190","author":"Hildebrandt","year":"2020","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.transci.2022.103367_bib0180","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1399-0012.2012.01604.x","article-title":"Defibrotide fort he prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review","volume":"26","author":"Zhang","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transci.2022.103367_bib0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1705696","article-title":"Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease","volume":"40","author":"Dignan","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.transci.2022.103367_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102827","article-title":"Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of Turkish Hematology Research and Education Group (ThREG)","volume":"59","author":"Soyer","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2022.103367_bib0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2017.08.029","article-title":"Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count","volume":"24","author":"Kennedy","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050222000179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050222000179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:25:34Z","timestamp":1741623934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050222000179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1473050222000179"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2022.103367","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2022.103367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103367"}}